.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Colorcon
Queensland Health
Citi
Accenture
Argus Health
QuintilesIMS
Cipla
Moodys
Mallinckrodt

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
Abstract: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N--CH2COCH2-CH2CO--OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms; and R2 represents a hydrogen atom or a group R1, and both R2 groups may be the identical or different), and their use in diagnosis and photochemotherapy of disorders or abnormalities of external or internal surfaces of the body, and products and kits for performing the invention.
Inventor(s): Gierskcky; Karl E. (Oslo, NO), Moan; Johan (Oslo, NO), Peng; Qian (Oslo, NO), Steen; Harald (Oslo, NO), Warloe; Trond (Oslo, NO), Bjorseth; Alf (Oslo, NO)
Assignee: PhotoCure ASA (Oslo, NO)
Filing Date:Nov 29, 2005
Application Number:11/290,275
Claims:1. A method for the treatment of urinary bladder abnormalities responsive to photochemotherapy in a patient in need thereof, comprising: i) administering to a urinary bladder a composition comprising hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) exposing said lining of the urinary bladder to photoactivating light in the spectrum 300-800 nm.; iii) ascertaining the level of fluorescence; iv) comparing the level of fluorescence to control levels to locate abnormalities in the bladder; and v) treating the abnormalities by (a) continued build up of fluorescence or (b) through further application of the composition at the located site of the abnormalities.

2. The method of claim 1 wherein the abnormality is bladder cancer.

3. The method of claim 2 wherein the photoactivating light is in the spectrum 350-640 nm.

4. The method of claim 3 wherein the ratio of the level of fluorescence of the abnormality to control levels of fluorescence is greater than 8.

5. The method of claim 4 wherein the photoactivating light is applied via an optical fiber inserted through a needle.

6. The method of claim 5 wherein the photoactivating light is applied after surgically accessing the urinary bladder.

7. A method of using hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition for the treatment of abnormalities of a urinary bladder in a patient in need thereof, comprising: i) putting in a first container hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) putting in a second container a physiologically acceptable carrier; and iii) putting said first container and said second container in a third container.

8. The method of claim 7 wherein the abnormality is bladder cancer.

9. A method for the treatment of urinary bladder abnormalities responsive to photochemotherapy in a patient in need thereof, comprising: i) administering to a urinary bladder a composition comprising hexyl 5-aminolevulinate or a pharmaceutically acceptable salt thereof; ii) exposing said lining of the urinary bladder to photoactivating light in the spectrum 300-800 nm. and iii) treating the abnormalities by (a) continued build up of fluorescence or (b) through further application of the composition at the located site of the abnormalities.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Deloitte
QuintilesIMS
Cerilliant
McKesson
Chubb
Express Scripts
Colorcon
Accenture
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot